KIRKLAND, Wash., Jan. 18 /PRNewswire-FirstCall/ -- In response to the recent comments by certain plaintiff law firms regarding their filing of class action lawsuits, CellCyte Genetics Corporation (the "Company") (OTC Bulletin Board: CCYG) asserts that the pending claims are without merit and will be shown to be so in a court of law. To that end, CellCyte has retained the international law firm of Duane Morris LLP as its counsel and will defend itself vigorously in these matters. Concurrently, the Company will continue its commitment to and pursuit of its policy of ensuring that its operations comply with all applicable laws.
"CellCyte is a sound enterprise, with a solid plan to develop our technology for the delivery of adult stem cells to the human heart," said Gary A. Reys, Chairman and CEO of CellCyte. "Our highly skilled management team is committed to developing this and our other technologies to their fullest potential. We look forward to meeting these legal claims in court."
CellCyte Genetics is actively engaged in carrying out its business plan and corporate objectives as stated in the company's literature and filings. This fact is evidenced by such major advances as its move to the Company's new 26,000 foot facility and corporate offices in Bothell, Washington last month - the result of months of planning, investment and very hard work by a dedicated staff.
About CellCyte Genetics
CellCyte Genetics, a Washington State company, is an emerging
biotechnology company engaged in the principal business of the discovery,
development and commercialization of breakthrough stem cell enabling
For further information see: http://www.cellcyte.com.
Symbol: OTCBB - CCYG; Frankfurt/Berlin Symbol - LK6 WKN. No.: A0MLCV.
Safe Harbor Statement
THIS NEWS RELEASE CONTAINS "FORWARD-LOOKING STATEMENTS", AS THAT TERM
IS DEFINED IN SECTION 27
|SOURCE CellCyte Genetics Corporation|
Copyright©2008 PR Newswire.
All rights reserved